SOUTH SAN FRANCISCO, Calif.,
Feb. 20, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its fourth quarter and year end 2019
financial results after market close on Thursday, February 27, 2020. Rigel senior
management will follow the announcement with a live conference call
and webcast at 4:30pm Eastern Time
(1:30pm Pacific Time) to discuss the
financial results.
Participants can access the live conference call by dialing
(877) 407-3088 (domestic) or (201) 389-0927
(international). The conference call and accompanying slides
will also be webcast live and can be accessed from the Investor
Relations section of the company's website at www.rigel.com. The
webcast will be archived and available for replay for 90 days after
the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate), the only
oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of
adult patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. The product has been
approved by the European Commission for the treatment of chronic
immune thrombocytopenia in adult patients who are refractory to
other treatments, and will be marketed in Europe under the name TAVLESSE®
(fostamatinib).
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a recently
completed Phase 1 study of R8351, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) inhibitor
program; and an ongoing Phase 1 study of R5521, a
proprietary molecule from its receptor-interacting protein kinase
(RIP) inhibitor program. In addition, Rigel has product candidates
in clinical development with partners Aclaris Therapeutics,
AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Please see www.TAVALISSE.com for the full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-financial-results-301008142.html
SOURCE Rigel Pharmaceuticals, Inc.